T7744

Piperaquine tetraphosphate tetrahydrate is a potent anti-parasites agent.

Apitegromab (SRK-015) is a new myostatin inhibitor, an antibody targeting myostatin precursor, which can be used to study neuromuscular diseases including spinal muscular atrophy.

Codrituzumab (GC3) is a humanized antibody against the glypican-3 hepatocellular carcinoma protein that can be used in combination with sorafenib to study incurable advanced hepatocellular carcinoma (HCC).

KRN330 is a fully human anti-A33 monoclonal antibody that can be used to study advanced rectal cancer.

Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.

Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is a mouse γ-type anti-recombinant antibody. It can specifically induce an antibody response against Neu-glycolyl GM3 ganglioside (NeuGcGM3), which is overexpressed in a variety of solid tumors. Racotumomab reacts with gangliosides containing NU-Glycolyl (NeuGc), thioglycosides, and other antigens expressed in tumors. Racotumomab has anti-cancer activity and can be used in the study of lung cancer.

Ecromeximab (KW2871) is a mouse chimeric monoclonal antibody targeting ganglioside GD3 and can be used to study malignant melanoma.

Dinutuximab is a recombinant chimeric monoclonal antibody targeting GD2, with potential anti-cancer activity, used in high-risk neuroblastoma research.

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers.

Tabituximab (ONC-005) is a humanized monoclonal antibody that targets FZD10 (FZD10), a Wnt receptor, and exhibits antitumor activity. Tabituximab binds to FZD10 on the surface of tumor cells, blocking the binding of Wnt ligands to the receptor, thereby inducing tumor cell apoptosis and inhibiting tumor invasion and metastasis. Tabituximab can be used in research on tumors and immune system diseases.